Maitansine, a cytotoxic agent, inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site.
Structure of 35846-53-8
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
5 mg | $629 | In stock | |
25 mg | $1574 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|
NCT01472887 | Diffuse Large B-cell Lymphoma | Phase 2 | 2018-01-25 | Sanofi | Completed |
NCT02221505 | cKIT-positive Solid Tumors | Phase 1 | 2016-04-05 | Novartis Pharmaceuticals | Terminated |
NCT04596150 | Neoplasms | Phase 2 | 2021-10-28 | CytomX Therapeutics | Recruiting |
NCT02947152 | Epithelial Ovarian Cancer | Phase 1 | 2020-12-08 | Novartis Pharmaceuticals | Terminated |
NCT01440179 | Acute Lymphocytic Leukaemia | Phase 2 | 2014-08-27 | Sanofi | Terminated (The study is stopped due to very modest activity compared to competitors) |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.